ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Kits > FcRn (FCGRT & B2M) > FRT-01

Human FcRn binding Kit (TR-FRET)

For research use only.
    Product Details
    Assay TypeInhibition-TR-FRET
    AnalyteHuman IgG, Human IgG Fc protein, Human FcRn inhibitors, Anti-human FcRn antibody
    Format100T/500T
    ReactivityHuman
    Regulatory StatusRUO
    SensitivityIC50=20.14μg/mL
    Standard Curve Range0.24 μg/mL-1000 μg/mL
    Assay Time1 hr
    Suitable Sample TypeFor the binding of IgG Fc region to the human FcRn receptor
    Sample volume10 μL
  • Background
    FcRn is a heterodimer comprising a β2-microglobulin (β2m) light chain and a major histocompatibility complex class I-like heavy chain. It is widely accepted that the interaction of IgGs with the Fc FcRn plays a critical role in regulating IgG homeostasis in vivo. FcRn interacts with the CH2-CH3 portion of the Fc domain of IgGs in a tightly regulated pH-dependent manner with high affinity binding occurring at an acidic (pH 6.0) and weak to no binding interactions as the pH is raised to neutral (pH 7.4). FcRn is responsible for the extended serum half-life of IgG and also serum albumin, and for the transport across endothelial and epithelial barriers, increasing the overall bioavailability of IgG and serum albumin. The binding affinity between FcRn and IgG are commonly used to characterize the metabolic levels of antibody drugs.

    The Human FcRn Binding Kit (TR-FRET) takes advantage of binding of Europium-chelate labeled FcRn (donor) and FA labeled Human IgG1 antibody (acceptor) in a homogeneous (no wash) TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) competition assay to measure the interaction between human FcRn and antibody drug candidates or FcRn inhibitors. It is designed to facilitate the half-life evaluation of antibody drug candidates, and also high-throughput screening of FcRn inhibitors within 0.5-1 hours. It is highly sensitive, has a short detection time and easy to use.

  • Application

    This kit is designed to facilitate the half-life evaluation of antibody drug candidates, and also high-throughput screening of FcRn inhibitors. It can also be used as a universal detection tool to identifying the ability of antibody drugs to bind to FcRn.

    It is for research use only.

  • Storage
    1. Unopened kit should be stored at 2℃-8℃ upon receiving.

    2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

    Materials Provided
    IDComponentsSize
    FRT01-C01Human FCRN&B2M Heterodimer Protein Europium-chelate2.7 μg/100 tests
    13.5 μg/500 tests
    FRT01-C02FA labeled human IgG antibody2.4 μg/100 tests
    12 μg/500 tests
    FRT01-C03Human IgG standard200 μg/100 tests
    1 mg/500 tests
    FRT01-C04Sample Dilution Buffer10 mL/100tests & 500tests
    FRT01-C05Detection Buffer10 mL/100tests & 500tests
  • Assay Principles
    This Human FcRn binding Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use the mixture of biotinylated FcRn and Europium-chelate labeled streptavidin as the donor, FA labeled Human IgG1 antibody as the acceptor.
    Your experiment will include 3 simple steps:
    a) Mix the sample or Human IgG standard in the kit with Human FCRN&B2M Heterodimer Protein Europium-chelate (Donor) and incubate at room temperature for 0.5 hours.
    b) Add FA labeled human IgG antibody (Acceptor) and incubate at room temperature for at least 0.5 hours.
    c) Use the TR-FRET module of a microplate reader to read the fluorescence signal at 665nm and 620nm. Calculate the Ratio based on the formula Ratio= "Signal 665 nm" /" Signal 620 nm " × 10^4. The Ratio value is negatively correlated with the antibody content in the sample.
    - When the sample does not contain FcRn binding components, the donor and acceptor are in close proximity because of the binding of FcRn and FA labeled Human IgG1 antibody. The 620nm signal emitted by the donor under specific light source excitation is received by the acceptor, emitting a 665nm signal.
    - When the sample contains FcRn binding components, the components inhibit the binding between the donor and acceptor and thereby prevents FRET from occurring.

    Assay Principles

Bioactivity-TR-FRET Please refer to DS document for the assay protocol.
 FcRn (FCGRT & B2M) TR-FRET

Inhibition Assay of interaction of Human FcRn and Human IgG1 antibody by Human IgG standard in a homogeneous (no wash) TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) competition assay, with a typical IC50 of 20.14 μg/mL (QC tested).

 FcRn (FCGRT & B2M) TR-FRET

The kit has been used to detect different subclasses of Human IgG Fc proteins, which exhibit different IC50 results as expected.

 FcRn (FCGRT & B2M) TR-FRET

The kit has been used to detect different subclasses of Human IgG, which exhibit different IC50 results as expected.

 FcRn (FCGRT & B2M) TR-FRET

The kit has been used to detect the binding activity between Human FcRn and Human IgG standard under different pH. The IC50 shows a significant increase with increasing pH, which corelates with a decreased binding between Human FcRn and Human IgG standard.

 FcRn (FCGRT & B2M) TR-FRET

The half-lives of these 3 monoclonal antibodies currently in clinical use generally correlate with the binding affinity to FcRn. The kit has been used to detect 3 FDA approved antibody drugs of different binding affinity to FcRn, and the IC50 trends are consistent with affinity constant from SPR as well as the actual in vivo half-life published.

 FcRn (FCGRT & B2M) TR-FRET

The kit is suitable for the detection of FcRn inhibitors. It shows that both Efgartigimod and its biosimilar, Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) His Tag (Cat. No. IG1-H52H8) exhibit good inhibitory activity in this TR-FRET competition assay.

  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 210,000

価格(JPY) : 700,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Approved

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone